Conference Reports for NATAP

63rd Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA Nov 9-12 2012 Back

Chronic hepatitis B patients with advanced fibrosis/compensated cirrhosis can benefit from peginterferon alfa-2a (40KD): improved or comparable response rates versus mild fibrosis in the phase III studies       Reported by Jules Levin   Presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 9-13, 2012, Boston, USA   T. Piratvisuth,1 P. Marcellin,2 E. Gane,3 J. Jia,4 F. Bonino,5 G. Germanidis,6 S. Woon Paik,7 C. Yurdaydin,8 V. Rothe,9 L. Regep,10 C. Wat,11 K-X. Luo,12 R. Jin,13 Y-F. Liaw14   1NKC Institute of Gastroenterology and Hepatology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Thailand; 2Service d'Hépatologie and INSERM CRB3/U773, University Paris-Diderot, Clichy, France; 3New Zealand Liver Transplant Unit, University of Auckland, Auckland, New Zealand; 4Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China; 5Digestive and Liver Disease Division and General Medicine 2 Unit, University Hospital of Pisa, Pisa, Italy; 6First Department of Internal Medicine, AHEPA Hospital of the Aristotle University Medical School, Thessaloniki, Greece; 7Division of Gastroenterology, Samsung Medical Center, Sungkyunkwan University, Seoul, Korea; 8Department of Gastroenterology, University of Ankara Medical School, Ankara, Turkey; 9IST GmbH, Mannheim, Germany; 10F. Hoffmann-La Roche, Basel, Switzerland; 11Roche Products Limited, Welwyn Garden City, United Kingdom; 12Department of Infectious Diseases, Nanfang Hospital, Guangzhou, China; 13Beijing Friendship Hospital, Capital Medical University, Beijing, China; 14Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan Author disclosures: T. Piratvisuth: advisory board member for Roche, Novartis and Merck; speaker for Roche, Novartis, Merck, Glaxo SmithKline and Bristol-Myers Squibb; received grants from Roche, Novartis and Bristol-Myers Squibb. P. Marcellin: received grants from Roche, Gilead Sciences, Janssen/Tibotec and Merck; speaker and/or expert for Roche, Gilead Sciences, Bristol-Myers Squibb, Vertex, Novartis, Janssen/Tibotec, Merck and Abbott; investigator for Roche, Gilead Sciences, Bristol-Myers Squibb, Vertex, Novartis, Janssen/Tibotec, Merck, Boehringer Ingelheim, Abbott and Pfizer. E. Gane: advisory board member for Roche, Gilead, Novartis, Abbott and Janssen/Tibotec; speaker for symposia sponsored by Roche, Gilead and Novartis. J. Jia: received honoraria for giving lectures and attending consultation meetings for Bristol-Myers Squibb, Merck, Novartis and Roche. C. Yurdaydin: advisory board member for Merck and Gilead Sciences; speaker for Roche, Gilead Sciences, Bristol-Myers Squibb and Merck. L. Regep: F. Hoffmann-La Roche employment. C. Wat: Roche Products Ltd employment. Y-F. Liaw: global advisory board member for Roche, Bristol-Myers Squibb, Novartis and Gilead Sciences. F. Bonino, G. Germanidis, SW. Paik, V. Rothe, K-X. Luo and R. Jin have no disclosures.